Metabolic Effects of Melatonin in Patients Treated With Second Generation Antipsychotics
This clinical trial investigated the effects of melatonin on metabolic side effects in patients treated with second generation antipsychotics for schizophrenia or bipolar disorder. The study aimed to address the significant metabolic risks associated with SGA, which include weight gain and dysregulation of glucose and lipids.
Indication: Second Generation Antipsychotic Induced Metabolic Adverse Effects
Modality: gene therapy
Target: Metabolic disturbances associated with Second Generation Antipsychotics (SGA)
Sponsor: Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente
Source URL: ClinicalTrials.gov
Source updated: Mar 14, 2013
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Metabolic disturbances associated with Second Generation Antipsychotics (SGA)
View original source fields
Condition raw: Second Generation Antipsychotic Induced Metabolic Adverse Effects
Condition normalized: Second Generation Antipsychotic Induced Metabolic Adverse Effects
Modality raw: Second Generation Antipsychotic Induced Metabolic Adverse Effects
Modality normalized: gene therapy
Target raw: Metabolic disturbances associated with Second Generation Antipsychotics (SGA)
Target normalized: Metabolic disturbances associated with Second Generation Antipsychotics (SGA)